In:
European Journal of Immunology, Wiley, Vol. 46, No. 2 ( 2016-02), p. 291-299
Abstract:
IL‐17 mediates immune responses against extracellular pathogens, and it is associated with the development and pathogenesis of various autoimmune diseases. The expression of IL‐17 is regulated by various intracellular signaling cascades. Recently, it has been shown that mechanistic target of rapamycin (mTOR) signaling, comprised mainly of mTORC1 signaling, plays a critical role in IL‐17 expression. Here, we review the current knowledge regarding mechanisms by which mTORC1 regulates IL‐17 expression. mTORC1 positively modulates IL‐17 expression through several pathways, i.e. STAT3, ‐HIF‐1α, ‐S6K1, and ‐S6K2. Amino acids (AAs) also regulate IL‐17 expression by being the energy source for Th17 cells, and by activating mTORC1 signaling. Altogether, the AA‐mTORC1‐IL‐17 axis has broad therapeutic implications for IL‐17‐associated diseases, such as EAE, allergies, and colitis.
Type of Medium:
Online Resource
ISSN:
0014-2980
,
1521-4141
DOI:
10.1002/eji.201545886
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1491907-2
Permalink